欧美成一级-欧美成在人线a免费-欧美传媒影-欧美大逼逼-欧美大成色www永久网站婷-欧美大胆a级视频

Cell Therapy
Universal Cell Platform
Quikin CAR-T Platform
Enhanced T Cell Platforms

Universal Cell Platform


Universal Cell Platform (TyUCell?) refers to the use of gene editing technology to transform allogeneic immune cells to eliminate immune rejection. On the basis of ensuring the safety and effectiveness of cell products, it realizes the generalization of immune cell therapy products. Tyucell cell products have the advantages of low cost, wide application range, short production cycle, stable preparation process and good therapeutic effect. The platform can be used for clinical treatment after a large number of expansion of cells from healthy donors. At the same time, it can realize the large-scale and batch production of cell products, significantly reduce the production cost, shorten the waiting time of patients, and provide modern cell therapy products that meet the urgent needs of clinic.


The development of the era of gene therapy

In 2023, the world's first all human targeted BCMA CAR-T therapy "FUCASO" (Equecabtagene Autoleucel) was approved for sale in China for the treatment of recurrent or refractory multiple myeloma (R/R MM)
In 2022, Cilta cel, the first CAR-T cell therapy for the treatment of r/r MM in China, was approved by the FDA for marketing
In 2021, China's first CAR-T product, Aquilensai injection, was approved for marketing by the Chinese NMPA for post-treatment relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
In 2020，CRISPR/Cas9 gene editing technology wins Nobel Prize in Chemistry
In June 2019, zynteglo, the world's first gene therapy drug ,was approved for marketing by the EU EMA for the treatment of thalassemia
In May 2019, Zolgensma, the world's first gene therapy drug,was approved for marketing by the FDA for the treatment of SMA
In 2018, the first CRISPR/Cas9-based in vivo gene therapy clinical trial (EDIT-101) was approved by the FDA for the treatment of Leber Congenital Amaurosis Type 10 (LCA)
In 2017, Kymriah, the world's first CAR-T product, received FDA approval to market for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL)
In 2016, the first generation of single-base editors were developed
In November 2013, the third generation gene editing technology CRISPR/Cas9 (clustered regularly spaced short palindromic repeats) was introduced
In 2012, Glybera, the world's first AAV gene therapy drug, was approved for marketing by the EU EMA for the treatment of lipoprotein lipase deficiency (LPLD)
In 2010, TALENs (transcription activation-like effector nucleases), a second-generation gene editing technology, was introduced
In 2003, Gendicine, the world's first gene therapy drug, was approved for marketing by the NMPA in China for the treatment of head and neck squamous cell carcinoma (HNSCC)
In 2001, the first generation of gene editing technology ZFNs (zinc finger nucleases) was introduced
In 1990, the world's first clinical trial of gene therapy was approved by the FDA for the treatment of adenosine deaminase deficiency (ADA-SCID)
Back to top
主站蜘蛛池模板： 国产在线观看无码 | 精品精品国产欧美在 | 亚洲乱码 | 不卡一区二区三区卡 | 亚洲一区二区三区一六视频在线 | 国产成人综合在线观看网站 | 职场同事娇妻素人国产精品 | 日韩精品无码免费专区午夜 | 国产精品一卡 | 亚洲一区二区无码影院 | 亚洲日本中文字幕在线2025 | 在线高清mv视频 | 97人妻天天爽夜夜爽二区 | 特级深夜a级毛片免费观看 特级一级黄色毛片 | 亚洲色国产欧美日韩 | 91视频中文 | 91麻豆精品国产片在线观看 | 99v久久综合狠狠综合久久 | 亚洲精品白浆高清久久久 | 欧美日韩国产a区 | 国产性爱网站 | 欧美αv日韩αv另类综合 | 99久久免费国产精精品 | 日韩一区二区三区在线成人 | 国产一区二区手机在线 | 国产精品日韩专区一区二区 | 日语双语字幕日剧网站 | 亚洲精品99久久久久中文字幕 | 91中文字幕在线永久在线观看 | 精品国产第一页 | 亚洲不卡无码αv中文字幕 亚洲不卡一区二区三区 | 国产精品国语刺激对白在线观看 | 国产av福利片一二三四区 | 在线一区免费视频播放 | 国产一区二区三区啪啪啪 | 精品国产v无码大片在线观看 | 亚洲精品国产字幕 | 亚洲婷婷五月天av | 成视频年人黄网站免费视频 | 海量正版高清视频在线观看 | 国产精品ⅴ无码大片在线看 |